1cP-MiPLA

1cP-MiPLA
Clinical data
Other names1cP-MIPLA; 1-Cyclopropanoyl-MiPLA; 1-Cyclopropanoyl-N-methyl-N-isopropyllysergamide; 1-(Cyclopropanecarbonyl)-N,6-dimethyl-N-(propan-2-yl)-9,10-didehydroergoline-8β-carboxamide
Routes ofadministrationOral[1][2][3]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • (6aR,9R)-4-(cyclopropanecarbonyl)-N,7-dimethyl-N-(propan-2-yl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChemCID
ChemSpider
Chemical and physical data
FormulaC24H29N3O2
Molar mass391.515 g·mol−1
3D model (JSmol)
  • CN1C[C@@H](C=C2[C@H]1Cc1cn(c3c1c2ccc3)C(=O)C1CC1)C(=O)N(C(C)C)C
  • InChI=1S/C24H29N3O2/c1-14(2)26(4)23(28)17-10-19-18-6-5-7-20-22(18)16(11-21(19)25(3)12-17)13-27(20)24(29)15-8-9-15/h5-7,10,13-15,17,21H,8-9,11-12H2,1-4H3/t17-,21-/m1/s1
  • Key:DBIYDHUGEKMIHZ-DYESRHJHSA-N

1cP-MiPLA, also known as 1-cyclopropanoyl-MiPLA or 1-cyclopropanoyl-N-methyl-N-isopropyllysergamide, is a presumed psychedelic drug of the lysergamide family.[1][2][3] It is the 1-cyclopropanoyl derivative of MiPLA (N-methyl-N-isopropyllysergamide) and is thought to be a prodrug of MiPLA.[1][2][3] 1cP-MiPLA has been encountered as a novel designer drug online[1] and in Japan.[2][3]

Use and effects

1cP-MiPLA has been sold in the form of blotter tabs containing doses of 200 μg per tab.[1] Data on the effects of 1cP-MiPLA at different doses are not available.[1]

Interactions

Pharmacology

1cP-MiPLA is assumed to act as a prodrug of MiPLA via deacylation.[2][3] Relatedly, it is assumed to act as a serotonin receptor agonist, including of the serotonin5-HT2A receptor, and to be a serotonergic psychedelic.[1]

Chemistry

Analogues

Analogues of 1cP-MiPLA include MiPLA, 1P-MiPLA, and 1cP-AL-LAD, among others.

History

1cP-MiPLA was first encountered as a novel designer drug online in 2020[1] and in Japan by 2022.[2][3]

Society and culture

Canada

1cP-MiPLA is not a controlled substance in Canada as of 2025.[4]

Russia

1cP-MiPLA is a schedule I controlled substance in Russia.[1]

United States

1cP-MiPLA is not an explicitly controlled substance in the United States.[5] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

References

  1. ^ abcdefghi"1cP-MIPLA". АИПСИН (in Russian). Retrieved 26 July 2025.
  2. ^ abcdefTanaka R, Kawamura M, Mizutani S, Kikura-Hanajiri R (2022). "Analyses of LSD analogs in illegal products: The identification of 1cP-AL-LAD, 1cP-MIPLA and 1V-LSD". Toxicologie Analytique et Clinique. 34 (3): S171. Bibcode:2022ToxAC..34Q.171T. doi:10.1016/j.toxac.2022.06.295.
  3. ^ abcdefTanaka R, Kawamura M, Mizutani S, Kikura-Hanajiri R (2023). "Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products"(PDF). Forensic Toxicology. 41 (2): 294–303. doi:10.1007/s11419-023-00661-1. ISSN 1860-8965. PMC 10310582. PMID 36809464. Retrieved 26 July 2025.
  4. ^"Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
  5. ^Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026)(PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
Retrieved from "https://en.wikipedia.org/w/index.php?title=1cP-MiPLA&oldid=1334202152"